Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Adds Capital Markets Expert and Best-Selling Author, Steve Kann and Strategic and Financial Advisory Veteran, Andre Peschong, as Managing Directors NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Dominar...
Eric Newman Appointed as Executive Vice President NEW YORK , March 15, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominar...
Dr. Cosme Ordoñez Appointed Head of Investment Banking NEW YORK , March 12, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dom...
Adds High Producing Private Equity Team of Larry Cohen and John Russo and Seasoned Specialty Finance Executive Michael Siek NEW YORK , March 7, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: ...
Adds David Reimer, Peter Sandler and team of five experienced wealth management professionals NEW YORK , March 6, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today annou...
Adds seasoned Wealth Advisors, Michael Schiavello and Billy Takos, and team of 12 experienced wealth advisors NEW YORK , March 5, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Compa...
NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, acted as lead underwriter to Unusua...
AIkido Pharma (AIKI) stock is skyrocketing on Tuesday but it's not due to any positive news from the biotechnology company. The post Why Is AIkido Pharma (AIKI) Stock Up 1,400%?...
A 1 for 17 reverse stock split of AIkido Pharma, Inc. (NASDAQ: AIKI) has gone into effect. These are the details....
